A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma
A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).
Inclusion Criteria:
Exclusion Criteria:
Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
Prior allogenic stem cell or solid organ transplantation
Untreated symptomatic central nervous system (CNS) metastases
Clinically significant ascites as defined by:
i) Prior ascites that required treatment and requires on-going prophylaxis, or ii) Current ascites requiring treatment
Other protocol-defined inclusion/exclusion criteria apply
Kashiwa-shi, Chiba 2778577, Japan
Chuo-ku, Tokyo 104-0045, Japan
District Taichung City, Tai Zhong Shi 404, Taiwan